12 / 73 resources displayed
-
Fact Sheet
First-in-Human to Proof-of-Concept
Our Translational Pharmaceutics approach enables First-in-Human studies by re-engineering the transition of your drug molecule into clinical development and shortening the timeline to Proof-of-Concept.
-
Fact Sheet
PPD & Quotient Pediatric Partnership
Through our partnership with PPD, we can provide one solution to execute an entire pediatric program with the potential for one contract and a single point of contact.
-
Webinar
Pharmaceutical Spray Drying to Overcome Poor Drug Solubility
Overcoming poor drug solubility is a common and challenging task facing the formulation scientist today.
-
Webinar
How to Reduce the Time and Cost for Optimizing Drug Product Formulations
Join industry experts John McDermott, Executive Director of Drug Product Optimization, and Kieran Crowley, Senior Scientific Director, both from Quotient Scienbces, as they outline studies and metrics in drug delivery and drug product optimization.
-
Webinar
How to Accelerate Modified Release Drug Product Development
Are you struggling with your drug product development timeline? Are ongoing drug formulation issues leading to escalating costs and missed deadlines?
-
Webinar
First-in-Human to Proof-Of-Concept: Addressing Development Challenges and Accelerating Timelines
Increasing pressure on R&D budgets means the design, speed and precision of early phase clinical programs is critical for success.
-
Webinar
Overcoming the Challenge of Poorly Soluble Drugs
How to Optimize Enabled Drug Products with Rapid Formulation Development and Clinical Testing (RapidFACT®).
-
Scientific Posters
Enhanced formulation decision-making in early phase clinical trials for parenteral products
This presentation describes the principles and applications of Translational Pharmaceutics: an R&D platform integrating formulation development, real-time adaptive GMP manufacturing and clinical testing in order to accelerate drug development cycles.
-
Case Studies
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is taking advantage of Quotient Sciences’ Translational Pharmaceutics® platform and First-In-Human program for the development of BCX4161, a promising candidate for the treatment of hereditary angioedema.
-
Case Studies
Stealth BioTherapeutics
Stealth BioTherapeutics is using real-time sterile manufacturing to enable a new route of administration.
-
Case Studies
MEI Pharma
MEI Pharma has leveraged Quotient's Translational Pharmaceutics® platform to expedite development of its next-generation cancer therapy ME-401.
-
Scientific Posters
Real-time drug product manufacturing to enable accelerated early clinical development of spray dried dispersion based formulations - AAPS 2017
This poster describes how adopting a real-time drug product manufacturing approach allowed initiation of the FIH study within 12 weeks of initiating SDD process transfer.